Rwanda joins other African countries in recalling J&J children’s cough syrup
The batch recalled was made by J&J in South Africa in May 2021 but Kenvue now owns the Benylin Paediatric syrup brand after a spin-off from J&J last year.
If you are not happy with the results below please do another search
The batch recalled was made by J&J in South Africa in May 2021 but Kenvue now owns the Benylin Paediatric syrup brand after a spin-off from J&J last year.
AbbVie released interim Phase III data for its calcitonin gene-related peptide receptor blocker Qulipta (atogepant), which demonstrated long-term safety and efficacy for patients in preventing chronic and episodic migraine.
An FDA advisory committee agreed that using minimal residual disease could be a viable surrogate endpoint for accelerated approval for drug development in multiple myeloma.
The agreement had two main components: allogeneic T-cell therapies for up to five cancer targets and personalized allogeneic T-cell-based programs. Both were still in the discovery phase at the time of the termination.
The cybersecurity firm BrandShield has taken down more than 250 websites selling fake versions of popular weight-loss and diabetes drugs in the GLP-1 class, the company’s CEO Yoav Keren told Reuters.
Neumora Therapeutics said the U.S. Food and Drug Administration (FDA) had placed a clinical hold on early-stage study of its experimental schizophrenia drug, sending its shares down more than 23% in premarket trading.
The announcement comes following the October 2023 acquisition of Healthware Group, an agency and innovation consultancy headquartered in Salerno, Italy. The new affiliate will operate from multiple offices across Italy, Finland, the United Kingdom and the United States, focused on innovation, transformation and client delight.
U.S. gene sequencing company Illumina’s plan to divest cancer diagnostic test maker Grail received the green light from EU antitrust regulators on Friday after having blocked the deal two years ago.
The European Medicines Agency announced on Friday that it has found no causal association between GLP-1 receptor agonists—a popular class of weight-loss treatments that include Novo Nordisk’s Wegovy (semaglutide)—and the risks of suicidal thoughts and actions.
A Florida judge on Tuesday dismissed Eli Lilly’s case against a compounding pharmacy, finding that the drugmaker cannot use state law in its campaign against reformulated versions of the company’s top-selling weight-loss and diabetes medication tirzepatide.